News coverage about Inovio Pharmaceuticals (NASDAQ:INO) has been trending somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.503189067894 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of Inovio Pharmaceuticals (NASDAQ INO) opened at $4.58 on Monday. Inovio Pharmaceuticals has a 52-week low of $4.20 and a 52-week high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). The business had revenue of $2.60 million for the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business’s revenue was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. sell-side analysts forecast that Inovio Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

A number of equities analysts have recently issued reports on INO shares. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Citigroup began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 target price for the company. Finally, BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Inovio Pharmaceuticals has an average rating of “Hold” and a consensus target price of $19.16.

COPYRIGHT VIOLATION WARNING: “Inovio Pharmaceuticals (INO) Earns Coverage Optimism Score of 0.13” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/12/04/inovio-pharmaceuticals-ino-earns-coverage-optimism-score-of-0-13.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.